Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma

Tanjina Kader & Sandro Santagata et al.

Abstract

High-grade serous ovarian cancer (HGSOC) originates from fallopian tube (FT) precursors. However, the molecular changes that occur as precancerous lesions progress to HGSOC are not well understood. To address this, we integrated high-plex imaging and spatial transcriptomics to analyze human tissue samples at different stages of HGSOC development, including p53 signatures, serous tubal intraepithelial carcinomas (STIC), and invasive HGSOC. Our findings reveal immune modulating mechanisms within precursor epithelium, characterized by chromosomal instability, persistent IFN signaling, and dysregulated innate and adaptive immunity. FT precursors display elevated expression of MHC class I, including HLA-E, and IFN-stimulated genes, typically linked to later-stage tumorigenesis. These molecular alterations coincide with progressive shifts in the tumor microenvironment, transitioning from immune surveillance in early STICs to immune suppression in advanced STICs and cancer. These insights identify potential biomarkers and therapeutic targets for HGSOC interception and clarify the molecular transitions from precancer to cancer.

Significance:

This study maps the immune response in FT precursors of HGSOC, highlighting localized IFN signaling, chromosomal instability, and competing immune surveillance and suppression along the progression axis. It provides an explorable public spatial profiling atlas for investigating precancer mechanisms, biomarkers, and early detection and interception strategies.

See related commentary by Recouvreux and Orsulic, p. 1093

Funding
Program for Interdisciplinary Neuroscience (PIN) FundingBridge Project between the Koch Institute at MIT and DC/HCC FundingVisual Analytics for Exploration and Hypothesis Generation Using Highly MultiplexedSpatial Data of Tissues and TumorsCarl H. Goldsmith Ovarian Cancer Translational Research Fund FundingAdvancing technologies for the collection and analysis of high dimensional immunoprofiles and tumor imagesCanary Foundation (THE CANARY FUND) FundingPathologyProject 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancerTechnical Development Unit 2: Intelligent Hyperspectral Imaging of Subcellular Molecular States at the Whole Organ LevelVisual Analytics for Exploration and Hypothesis Generation Using Highly MultiplexedSpatial Data of Tissues and TumorsGray Foundation FundingU.S. Department of Defense Grant W81XWH-22-1-0852Honorable Tina Brozman Foundation (Tina's Wish) FundingProject 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancerTechnical Development Unit 2: Intelligent Hyperspectral Imaging of Subcellular Molecular States at the Whole Organ LevelBWH President's Scholar award FundingAdvancing technologies for the collection and analysis of high dimensional immunoprofiles and tumor imagesMolecular, Cellular, and Tissue Characterization UnitLudwig Center at Harvard (Ludwig Center) FundingDr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) FundingThe Mike and Patti Hennessy Foundation FundingLudwig Center at Harvard FundingCanary Foundation FundingProject 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancerDr. Miriam and Sheldon G. Adelson Medical Research Foundation FundingHonorable Tina Brozman Foundation FundingTechnical Development Unit 2: Intelligent Hyperspectral Imaging of Subcellular Molecular States at the Whole Organ LevelProgram for Interdisciplinary Neuroscience FundingBWH President’s Scholar award Funding

NCI NIH HHS

U01 CA284207

National Cancer Institute (NCI)

R50-CA274277

NCI NIH HHS

P30 CA008748

NCI NIH HHS

P50 CA228991

Division of Cancer Prevention, National Cancer Institute (DCP, NCI)

U54-CA268072

National Cancer Institute (NCI)

U01-CA284207

Division of Cancer Prevention, National Cancer Institute (DCP, NCI)

P50-CA228991

NCI NIH HHS

U54 CA268072

NCI NIH HHS

R50 CA274277

National Cancer Institute (NCI)

U2C-CA233262

National Cancer Institute

U2C-CA233262

Division of Cancer Prevention, National Cancer Institute

P50-CA228991

National Cancer Institute

U01-CA284207

Division of Cancer Prevention, National Cancer Institute

U54-CA268072

National Cancer Institute

R50-CA274277